Nima Alidoust

CEO & Co-founder, Vevo Therapeutics · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

Nima Alidoust is the CEO and co-founder of Vevo Therapeutics. His work focuses on modeling whole human cells and studying cellular behavior in disease and response contexts.

7statements → 4claims → 2claims resolved → 3.43/5average certainty → 2.29/5average debate potential →

1 supported 1 partly supported 0 contradicted 2 not checkable as stated how the 4 claims stand · each chip opens the sources

1 prediction · 3 assertions · 1 opinion · 2 insights · every statement was checked. The prediction and assertions are the 4 claims: statements the public record can support or contradict. 2 are resolved, and 2 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Nima argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported

Alidoust: Prior public single-cell data totaled only 45M to 60M cells

“Before that, I think the number of human cells that we had, had been collated together it was in the order of 45, fifty million, if you are generous, sixty million single cell data points.”

Nima Alidoust Feb 25, 2025 ▶ 7:40 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Expressed certainty vs assessment result

none yet certainty 1

none yet certainty 2

100% certainty 3

50% certainty 4

none yet certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

How they sound: not measured why? →

We measure speaking style by listening to the audio itself, and a fair number needs at least 2,000 words from one person on tape we have measured. There is too little of Nima Alidoust on measured tape to publish a rate. This says nothing about how they speak.

What they said7 Episodes1

Everything Nima Alidoust said on No Priors that made the record, most notable first. Filter by type, assessment or year in the ledger →

Insight

Alidoust: Hypothesis-driven biology slowed progress, but falling costs enable unbiased data

“One thing that has been a Has been slowing the progress in bio is the fact that we have always been super hypothesis driven, and I think it has, the reason is that a lot of these experiments are expensive, you know, that they take a lot of time, a lot of resou…”

Nima Alidoust Feb 25, 2025 ▶ 18:18 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Assertion Not checkable as stated

Alidoust: Single-cell AI performance holds even after 99% data downsampling

“If you actually reduce the number of the sixty million, you down sample it by like, Even 99%. You know, you just use one percent of that data to train your models. Actually, the model's performance doesn't reduce that much. So it means that the information con…”

Nima Alidoust Feb 25, 2025 ▶ 8:10 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Opinion

Alidoust: Protein AI is past GPT-3 while cell models are at GPT-1

“I think in the protein, protein models, we are past GPT-III. when it comes to single cell models and virtual cell models, yeah, I think GPT-I to two right now. I think we're closer to GPT-I than two.”

Nima Alidoust Feb 25, 2025 ▶ 55:50 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Assertion Partly supported

Alidoust: Tahoe dataset expands public perturbational single-cell data fiftyfold

“I think when you put all of the perturbational data sets in the world together if you're generous, it's like one to two million single cell data points. And this is publicly available data. We don't know as much about, you know, what, what's inside different o…”

Nima Alidoust Feb 25, 2025 ▶ 12:14 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Prediction Not checkable as stated

Alidoust: Virtual cells will expand AI drug discovery to systems biology

“Virtual cells, in my opinion, are going to allow us to go beyond the language of structural biology and venture into the language of systems biology and understand how how the drug is interacting with the broader biological system.”

Nima Alidoust Feb 25, 2025 ▶ 41:18 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Assertion Supported

Alidoust: Prior public single-cell data totaled only 45M to 60M cells

“Before that, I think the number of human cells that we had, had been collated together it was in the order of 45, fifty million, if you are generous, sixty million single cell data points.”

Nima Alidoust Feb 25, 2025 ▶ 7:40 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Insight

Alidoust: 100 million single-cell data points equate to 200-300 billion tokens

“Think of it like a cell collection of for this data says 2000 to 5000 genes, and each gene and its expression is basically a token in what we're doing. So 200, like a hundred million single cell data points is akin to around 200 to three hundred billion tokens…”

Nima Alidoust Feb 25, 2025 ▶ 14:56 No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Appearances (1)